Changeflow GovPing Healthcare & Life Sciences Microglia From Pluripotent Stem Cells
Routine Notice Added Final

Microglia From Pluripotent Stem Cells

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260109946A1 on April 23, 2026, covering methods and compositions for generating microglial progenitor cells and microglial cells from pluripotent stem cells. Inventors include Panagiotis Douvaras, Scott Noggle, Stephen Chang, and Valentina Fossati. The application (No. 19423436) was filed on December 17, 2025, and covers both the cell generation methods and applications including methods of treatment and drug screening.

“The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.

What changed

The USPTO published a patent application disclosing methods and compositions for generating microglial progenitor cells and microglial cells from pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells. The application also covers cells produced using such methods, methods of treatment, and methods of drug screening utilizing these cells, as well as tissue culture media, supplements, and kits.

Affected parties in the biotechnology, pharmaceutical, and cell therapy sectors should review the disclosed methods and compositions to assess potential patent landscape implications, freedom-to-operate considerations, and opportunities for licensing or alternative approach development.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MICROGLIA DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAME

Application US20260109946A1 Kind: A1 Apr 23, 2026

Inventors

Panagiotis Douvaras, Scott Noggle, Stephen Chang, Valentina Fossati

Abstract

The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.

CPC Classifications

C12N 5/0622 A61K 35/30 C12N 5/0606 C12N 5/0618 G01N 33/5058 C12N 2500/90 C12N 2501/155 C12N 2501/22 C12N 2501/2334 C12N 2506/45

Filing Date

2025-12-17

Application No.

19423436

View original document →

Named provisions

Abstract Inventors CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260109946A1

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotechnology research Cell therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!